Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer
Journal of Clinical Oncology · 10.04.2024 · 42 (11) · 1288-1300
DOI: 10.1200/jco.23.01214 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2024. Verfasst von Patricia A Ganz und 45 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Los Angeles, Los Angeles, CA. Hauptthemen laut MEDLINE: Breast Neoplasms, Phthalazines, Piperazines, Quality of Life. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE The OlympiA randomized phase III trial compared 1 year of olaparib (OL) or placebo (PL) as adjuvant therapy in patients with germline BRCA1/2, high-risk human epidermal growth factor receptor 2–negative early breast cancer after completing (neo)adjuvant chemotherapy ([N]ACT), surgery, and radiotherapy. The patient-reported outcome primary hypothesis was that OL-treated patients may experience greater fatigue during treatment. METHODS Data were collected before random assignment, and at 6, 12, 18, and 24 months. The primary end point was fatigue, measured with the Functional Assessment of Chronic Illness Therapy-Fatigue scale. Secondary end points, assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30 item, included nausea and vomiting (NV), diarrhea, and multiple functional domains. Scores were compared between treatment groups using mixed model for repeated measures. Two-sided P values
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California, Los Angeles, Los Angeles, CA.
- Jonsson Comprehensive Cancer Center, Los Angeles, CA.
- NRG Oncology SDMC, The University of Pittsburgh, Pittsburgh, PA.
- Europa Donna-The European Breast Cancer Coalition, Milan, Italy.
- Europa Donna Slovenia, Ljubljana, Slovenia.
- Facing Our Risk of Cancer Empowered, Tampa, FL.
ORCID-Profile: Patricia A Ganz, Volkmar Müller, Sherko Kuemmel, Suzette Delaloge, Etienne Brain, Masakazu Toi, Eduardo-M de Dueñas, Seock-Ah Im, Priyanka Sharma, Peifen Fu, Heike Frauchiger-Heuer, Pauline Wimberger, Michael Friedlander, Sylvie Giacchetti, Toshimi Takano, Fernando Henao-Carrasco, Susan M Domchek, Edward C McCarron, Giovanna Rossi, Priya Rastogi, Richard D Gelber, David Cameron, Judy Garber, Charles E Geyer, Andrew N J Tutt
Förderung
- NCI NIH HHS
Zitieren
APA
Ganz, P. A., Bandos, H., Španić, T., Friedman, S., Müller, V., Kuemmel, S., Delaloge, S., Brain, E., Toi, M., Yamauchi, H., de Dueñas, E. M., Armstrong, A., Im, S. A., Song, C. G., Zheng, H., Sarosiek, T., Sharma, P., Geng, C., Fu, P., …, & Tutt, A. N. J. (2024). Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer. Journal of Clinical Oncology, 42(11), 1288-1300. https://doi.org/10.1200/jco.23.01214
Vancouver
Ganz PA, Bandos H, Španić T, Friedman S, Müller V, Kuemmel S, et al. Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer. Journal of Clinical Oncology. 2024;42(11):1288-1300. doi:10.1200/jco.23.01214
BibTeX
@article{Ganz2024,
author = {Ganz, Patricia A and Bandos, Hanna and Španić, Tanja and Friedman, Sue and Müller, Volkmar and Kuemmel, Sherko and Delaloge, Suzette and Brain, Etienne and Toi, Masakazu and Yamauchi, Hideko and de Dueñas, Eduardo-M and Armstrong, Anne and Im, Seock-Ah and Song, Chuan-Gui and Zheng, Hong and Sarosiek, Tomasz and Sharma, Priyanka and Geng, Cuizhi and Fu, Peifen and Rhiem, Kerstin and Frauchiger-Heuer, Heike and Wimberger, Pauline and t'Kint de Roodenbeke, Daphné and Liao, Ning and Goodwin, Annabel and Chakiba-Brugère, Camille and Friedlander, Michael and Lee, Keun Seok and Giacchetti, Sylvie and Takano, Toshimi and Henao-Carrasco, Fernando and Virani, Shamsuddin and Valdes-Albini, Frances and Domchek, Susan M and Bane, Charles and McCarron, Edward C and Mita, Monica and Rossi, Giovanna and Rastogi, Priya and Fielding, Anitra and Gelber, Richard D and Scheepers, Elsemieke D and Cameron, David and Garber, Judy and Geyer, Charles E and Tutt, Andrew N J},
title = {Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in g BRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {11},
pages = {1288--1300},
doi = {10.1200/jco.23.01214}
}
EUVIMED